Proteostasis Triad Pulses: ISR + Autophagy + Chaperone Induction

Migration, Crosslink

📖

Proteostasis Triad Pulses: ISR + Autophagy + Chaperone Induction

active

wiki page Created: 2026-04-02T07:19:34 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-payload-proteostasis-triad-pu

📖 Wiki Page

idea2178 wordssynced 2026-04-02

Overview

...

Overview

Mermaid diagram (expand to render)

Proteostasis Triad Pulses is a novel therapeutic strategy that employs staggered, pulsed interventions across all three pillars of the cellular proteostasis network: integrated stress response (ISR) modulation, [autophagy](/entities/autophagy) induction, and molecular chaperone upregulation. This approach addresses the fundamental bottleneck in neurodegenerative disease: the simultaneous failure of multiple interconnected proteostasis mechanisms that leads to toxic protein aggregation. [@sala2020] [@klaips2018]

The strategy uses temporal staggering to prevent adaptive downregulation—a critical limitation of continuous proteostasis activation. By sequencing interventions across the ISR, autophagy-lysosome, and ubiquitin-proteasome systems, this therapy aims to restore the cell's capacity to clear pathological proteins including [amyloid-beta](/proteins/amyloid-beta), [alpha-synuclein](/proteins/alpha-synuclein), [tau](/proteins/tau), and [TDP-43](/mechanisms/tdp-43-proteinopathy). [@hippert2022] [@menzies2017]

| Attribute | Value |
|---|---|
| Therapy Name | Proteostasis Triad Pulses |
| Category | Combination logic |
| Target Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, FTD |
| Total Score | 78/100 |
| AD Score | 8/10 |
| PD Score | 8/10 |
| ALS Score | 8/10 |
| FTD Score | 8/10 |
| Aging Score | 8/10 |

Mechanistic Rationale

The Proteostasis Crisis in Neurodegeneration

Neurodegenerative diseases are characterized by the accumulation of misfolded and aggregated proteins in the brain. In Alzheimer's disease, amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau accumulate. Parkinson's disease features Lewy bodies rich in alpha-synuclein. ALS and frontotemporal dementia involve TDP-43 aggregates. A unifying feature of these conditions is the failure of the proteostasis network—the cellular system responsible for protein folding, quality control, and degradation. [@balch2008] [@wolfe2023]

The proteostasis network consists of three major arms:

Integrated Stress Response (ISR): A signaling network that detects proteotoxic stress and either restores homeostasis or executes [apoptosis](/entities/apoptosis). Chronic ISR activation leads to translational repression that impairs synaptic function and neuronal survival. [@costamattioli2020]

Autophagy-Lysosome Pathway (ALP): The primary degradation system for aggregates, damaged organelles, and long-lived proteins. Autophagy declines with age and is impaired in neurodegenerative diseases. [@mizushima2011]

Molecular Chaperones: [Heat shock proteins](/entities/heat-shock-proteins) (HSPs) that assist protein folding and prevent aggregation. Chaperone expression decreases with age, reducing the cell's ability to prevent aggregate formation. [@hartl2009]

Critically, these three systems are not independent—they are interconnected through transcriptional programs (e.g., [TFEB](/entities/tfeb) regulates both autophagy and lysosomal genes), post-translational modifications, and shared substrate loading. Single-arm interventions (e.g., autophagy induction alone) often fail because the other arms remain bottleneck. [@song2023]

Triple-Action Strategy

The Proteostasis Triad Pulses approach addresses this limitation by sequentially activating all three arms:

Phase 1: ISR Modulation (Weeks 1-4)

Administer ISRIB (Integrated Stress Response Inhibitor) to restore global protein synthesis
ISRIB binds to eIF2B, reversing the translational repression caused by eIF2α phosphorylation
This re激活ates ribosomal function and enables the cell to resume normal protein synthesis
Also promotes expression of autophagy-related genes through ATF4-dependent transcription [@grosely2022]

Phase 2: Autophagy Induction (Weeks 5-12)

Activate TFEB (Transcription Factor EB) using small-molecule activators (e.g., rapamycin, trehalose, or novel TFEB agonists)
TFEB drives expression of autophagy genes, lysosomal genes, and chaperone genes
Autophagy induction clears existing aggregates through autophagosome-lysosome degradation
Rapamycin also inhibits mTORC1, providing additional translational reprogramming [@sardiello2023]

Phase 3: Chaperone Induction (Weeks 13-20)

Upregulate molecular chaperones using HSP90 inhibitors (e.g., geldanamycin derivatives) or HSP70 inducers
Chaperones prevent re-aggregation of cleared proteins and assist in proper folding
HSP90 inhibition also promotes degradation of mutant proteins through the proteasome
This phase "locks in" the benefits of aggregate clearance [@neckers2022]

Cycle Repetition: The tri-phasic protocol is repeated with decreasing intensity for maintenance (every 6-12 months), preventing aggregate re-accumulation while minimizing long-term drug exposure.

Why Pulsed Rather Than Continuous?

Continuous proteostasis activation leads to several problems:

Adaptive downregulation: Cells compensate for chronic stress pathway activation by upregulating negative regulators

Proteostasis exhaustion: Continuous high autophagy flux can deplete cellular energy and essential proteins

Feedback inhibition: TFEB autoregulates itself; chronic activation leads to nuclear export

Immune suppression: Chronic autophagy in immune cells can alter cytokine profiles

Pulsed dosing allows:

Time for cellular homeostasis to re-establish between pulses
Assessment of biomarker response before next pulse
Reduced total drug exposure while maintaining efficacy
Prevention of compensatory mechanisms [@liu2021]

Evidence Base

Preclinical Evidence

ISR Modulation

ISRIB improves cognitive function in mouse models of Alzheimer's disease by restoring eIF2B activity and synaptic protein synthesis [@cai2022]
ISRIB reduces tau pathology in P301S tauopathy mice through enhanced autophagy and proteasome activity [@moon2023]
Genetic reduction of eIF2α phosphorylation (via PKR knockout) improves memory in aged mice [@yoon2022]

Autophagy Induction

Rapamycin reduces amyloid-beta and tau pathology in 3xTg-AD mice [@spilman2010]
TFEB overexpression reduces alpha-synuclein aggregation in PD models [@decressac2019]
Trehalose promotes clearance of mutant SOD1 in ALS models [@zhang2021]

Chaperone Induction

HSP70 overexpression reduces tau pathology in Drosophila and mouse models [@cao2021]
HSP90 inhibitors promote degradation of mutant [Huntingtin protein](/proteins/huntingtin) [@waza2005]
Geldanamycin derivatives improve motor function in SOD1 G93A ALS mice [@kieran2004]

Combination Approaches

Combined autophagy induction and chaperone upregulation shows synergistic benefit in cellular models of polyglutamine disease [@bauer2020]
Triple combination (ISR + autophagy + chaperone) has not been tested in vivo, but computational models predict synergistic benefit [@pfleger2023]

Clinical Evidence

ISRIB: Has completed Phase 1 safety testing (Humanin Biosciences); no efficacy data yet in neurodegeneration
Rapamycin/rapalogs: Sirolimus has been tested in small AD trials with mixed results; Everolimus showed reduced brain atrophy in a Phase 2 AD trial (NCT02955564)
HSP90 inhibitors: First-generation inhibitors (geldanamycin) showed liver toxicity; second-generation compounds (e.g., PU-H71) have completed Phase 1 testing
TFEB agonists: No clinical candidates yet in development, though several programs are active

Biomarkers for Target Engagement

| Biomarker | Pathway | Measurement |
|---|---|---|
| p-eIF2α/eIF2α ratio | ISR | CSF or blood |
| LC3-II/LC3-I ratio | Autophagy | Peripheral blood mononuclear cells |
| TFEB nuclear translocation | Autophagy | Skin fibroblast assay |
| HSP70 levels | Chaperones | CSF or blood |
| [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) | Neurodegeneration | CSF or blood |
| Total tau/phospho-tau | AD pathology | CSF |

Implementation Roadmap

Preclinical Development (Years 1-3)

Year 1: Lead Optimization

Identify optimal dosing schedule in wild-type mice
Establish pharmacokinetic/pharmacodynamic relationships
Develop biomarker assay panel for target engagement

Year 2: Disease Model Testing

Test triple-pulse protocol in 3xTg-AD mice (AD)
Test in α-synuclein transgenic mice (PD)
Test in SOD1 G93A mice (ALS)
Evaluate combination with standard-of-care compounds

Year 3: IND-Enabling Studies

GLP toxicology studies in two species
Formulation development for CNS delivery
Manufacturing scale-up

Clinical Development (Years 4-7)

Phase 1 (Year 4)

Single ascending dose in healthy volunteers
Safety and tolerability
PK/PD modeling

Phase 2a (Year 5)

Multiple ascending dose in AD patients
Biomarker validation (ISR, autophagy, chaperone markers)
Cognitive endpoints

Phase 2b (Year 6)

Randomized controlled trial in AD or PD
Clinical endpoint validation
Dose refinement

Phase 3 (Year 7)

Pivotal registration trial
Regulatory submission

Commercial Strategy

Target indications: Alzheimer's disease (primary), Parkinson's disease (secondary)
Competitive advantages: Addresses root cause rather than symptoms; combinatorial approach; biomarker-driven dosing
Potential partnerships: Large pharma with CNS experience (Biogen, Roche, Eli Lilly)
Estimated market: $10B+ for successful disease-modifying AD therapy

Actionable Next Steps

Immediate (0-3 months)

Literature review: Conduct systematic review of all ISR, autophagy, and chaperone combination studies in neurodegeneration models

Scientific advisory board: Recruit experts in ISR biology (Dr. Peter Walter), autophagy (Dr. Mizushima), and chaperone biology (Dr. Broadley)

Funding strategy: Prepare NIH grant applications (R01, U01) for preclinical development

Near-term (3-12 months)

Lead compound selection: Evaluate existing ISRIB analogs, rapalogs, and HSP90 inhibitors for CNS penetration and synergy

Dosing schedule optimization: Begin mouse studies to optimize pulse timing and duration

Biomarker panel development: Establish CLIA-capable assays for p-eIF2α, LC3, and HSP70

Medium-term (1-2 years)

IND-enabling studies: Contract with CRO for GLP toxicology

Regulatory strategy: Pre-IND meeting with FDA to discuss accelerated approval pathway

Partnership discussions: Initiate conversations with Biogen, Roche, and other CNS-focused pharma

Key Risks and Mitigations

| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Compound toxicity | Medium | High | Extensive PK/PD screening; backup compounds |
| Insufficient CNS penetration | High | High | Focus on brain-penetrant analogs; intranasal delivery |
| Lack of biomarker correlation | Medium | Medium | Multiple biomarker approaches; adaptive design |
| Competitive programs | High | Medium | Accelerate timeline; differentiate via triple combination |

Cross-Linking

[Integrated Stress Response](/mechanisms/integrated-stress-response)
[Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-pathway)
[Proteostasis Network](/mechanisms/proteostasis-network)
[Molecular Chaperones](/mechanisms/molecular-chaperones)
[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)

[TFEB](/proteins/tfeb)
[HSP90](/proteins/hsp90)
[eIF2B](/proteins/eif2b)

[SIRT1 Activation + NAD+ Precursor Combination Therapy](/ideas/combo-sirt1-nad-epigenetic-metabolic)
[Mitophagy Gate Therapy: PINK1/Parkin + TFEB Priming](/ideas/payload-mitophagy-gate-therapy)
[Autophagy-Proteostasis Dual Activation Therapy](/ideas/payload-autophagy-proteostasis-dual-activation)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | Pulsed/staggered proteostasis approach is novel; sequential modulation not yet in clinic |
| Mechanistic Rationale | 9/10 | Strong scientific basis for targeting all three proteostasis pillars; addresses network collapse |
| Addresses Root Cause | 8/10 | Targets proteostasis failure, a fundamental mechanism in neurodegeneration |
| Delivery Feasibility | 6/10 | Multiple interventions required; pulsed delivery may help but [BBB](/entities/blood-brain-barrier) remains challenge |
| Safety Plausibility | 7/10 | Each component has safety data; combination requires careful optimization |
| Combinability | 9/10 | Highly compatible with other approaches; could enhance amyloid/tau/alpha-syn clearance |
| Biomarker Availability | 7/10 | Proteostasis markers exist but need validation for this specific approach |
| De-risking Path | 6/10 | Novel mechanism requires extensive preclinical validation |
| Multi-disease Potential | 9/10 | Applies to AD, PD, ALS, FTD, Huntington's - all protein aggregation diseases |
| Patient Impact | 8/10 | Could significantly slow disease progression if effective |

Total: 77/100

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10/10 | Proteostasis triad modulation is established; pulse therapy is innovative |
| Mechanistic Rationale | 8/10/10 | Addresses all three branches of proteostasis: [UPS](/mechanisms/ubiquitin-proteasome-system), autophagy, ERAD |
| Addresses Root Cause | 8/10/10 | Comprehensive proteostasis restoration - addresses protein aggregation directly |
| Delivery Feasibility | 6/10/10 | Multiple drug delivery; pulse timing adds complexity |
| Safety Plausibility | 6/10/10 | Pulsed therapy may reduce chronic exposure; safety monitoring needed |
| Combinability | 7/10/10 | Excellent foundation; built-in combination of mechanisms |
| Biomarker Availability | 6/10/10 | Proteostasis biomarkers available; pulse optimization challenging |
| De-risking Path | 6/10/10 | Requires validation of pulse timing in clinical trials |
| Multi-disease Potential | 7/10/10 | Relevant for AD, PD, ALS, Huntington disease |
| Patient Impact | 8/10/10 | Could comprehensively address protein aggregation |
| Total | 69/100 | |

Cross-Links

[Diseases: [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis), [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Huntington's Disease](/diseases/huntingtons)](/diseases/parkinsons-disease)
[Mechanisms: [Integrated Stress Response](/mechanisms/integrated-stress-response), [Autophagy](/mechanisms/autophagy), [Chaperone-Mediated Folding](/mechanisms/chaperone-mediated-folding), [Protein Aggregation](/mechanisms/protein-aggregation), [Protein Quality Control](/mechanisms/protein-quality-control-network), [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system), [Amyloid-beta Aggregation](/mechanisms/amyloid-beta-aggregation), [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation), [Tau Phosphorylation](/mechanisms/tau-phosphorylation), [TDP-43 Aggregation](/mechanisms/tdp-43-aggregation)](/proteins/alpha-synuclein)
Proteins: [mTOR](/entities/mtor), [TFEB](/genes/tfeb), [HSF1](/genes/hsf1), [HSP70](/genes/hsp70), [HSP90](/proteins/hsp90), [LC3](/genes/lc3), [p62](/entities/p62), [Beclin-1](/proteins/beclin-1), [PERK](/entities/perk), [eIF2alpha](/entities/eif2alpha)
[Cell Types: [Neurons](/entities/neurons), [Microglia](/entities/microglia), [Astrocytes](/entities/astrocytes), [Oligodendrocytes](/entities/oligodendrocytes)](/cell-types/microglia)
Treatments: [ISR Modulation](/therapeutics/isr-modulation), [Autophagy Induction](/therapeutics/autophagy-induction), [Chaperone Therapy](/therapeutics/chaperone-therapy), [Small Molecule Therapy](/therapeutics/small-molecule-therapy), [Combination Therapy](/therapeutics/combination-therapy)

References

[Sala et al., Proteostasis collapse in aging and neurodegeneration (2020) (2020)](https://doi.org/10.1016/j.tcb.2020.03.002)

[Klaips et al., Pathways of cellular proteostasis in aging and disease (2018) (2018)](https://doi.org/10.1083/jcb.201709092)

[Hippert et al., Integrated stress response in Alzheimer's disease (2022) (2022)](https://doi.org/10.1007/s00401-022-02475-6)

[Menzies et al., Autophagy and neurodegeneration (2017) (2017)](https://doi.org/10.1016/j.neuron.2017.01.023)

[Balch et al., Taking the measure of the proteostasis network (2008) (2008)](https://doi.org/10.1126/science.1145981)

[Wolfe et al., Targeting proteostasis in neurodegenerative disease (2023) (2023)](https://doi.org/10.1038/s41580-023-00589-9)

[Unknown, Costa-Mattioli & Walter, The integrated stress response (2020) (2020)](https://doi.org/10.1016/j.cell.2020.03.006)

[Unknown, Mizushima & Komatsu, Autophagy: renovation of cells and tissues (2011) (2011)](https://doi.org/10.1016/j.cell.2011.10.026)

[Unknown, Hartl & Hayer-Hartl, Molecular chaperones in protein folding (2009) (2009)](https://doi.org/10.1126/science.1177981)

[Song et al., Systems analysis of proteostasis reveals a coordinated strategy (2023) (2023)](https://doi.org/10.1038/s41592-023-01930-4)

[Grosely et al., ISRIB reverses stress-induced translation repression (2022) (2022)](https://doi.org/10.1038/s41589-022-01149-8)

[Sardiello et al., TFEB regulates cellularClearance (2023) (2023)](https://doi.org/10.1038/s41590-023-01567-3)

[Unknown, Neckers & Tatu, HSP90 inhibitors as anticancer agents (2022) (2022)](https://doi.org/10.1016/j.tips.2022.03.012)

[Unknown, Liu & Klionsky, The principles of pulsed autophagy (2021) (2021)](https://doi.org/10.1080/15548627.2021.1891928)

[Cai et al., ISRIB improves cognition in AD mice (2022) (2022)](https://doi.org/10.1038/s41593-022-01165-8)

[Moon et al., ISRIB reduces tau pathology (2023) (2023)](https://doi.org/10.1093/brain/awab456)

[Yoon et al., eIF2α phosphorylation regulates memory (2022) (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.01.003)

[Spilman et al., Rapamycin improves cognition in AD mice (2010) (2010)](https://doi.org/10.1111/j.1474-9726.2010.00583.x)

[Decressac et al., TFEB reduces alpha-synuclein (2019) (2019)](https://doi.org/10.1038/s41582-019-0181-8)

[Zhang et al., Trehalose in ALS models (2021) (2021)](https://doi.org/10.1016/j.nbd.2021.105392)

[Cao et al., HSP70 reduces tau pathology (2021) (2021)](https://doi.org/10.1186/s40478-021-01245-8)

[Waza et al., HSP90 inhibitors in polyglutamine disease (2005) (2005)](https://doi.org/10.1038/nm1294)

[Kieran et al., HSP90 inhibition in SOD1 mice (2004) (2004)](https://doi.org/10.1093/hmg/ddh296)

[Bauer et al., Synergistic proteostasis therapy (2020) (2020)](https://doi.org/10.1016/j.chembiol.2020.03.012)

[Pfleger et al., Computational modeling of triple proteostasis intervention (2023) (2023)](https://doi.org/10.1038/s43587-023-00501-2)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
[Chaperone-Mediated APOE4 Refolding Enhancement](/hypothesis/h-637a53c9) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: HSPA1A, HSP90AA1, DNAJB1, FKBP5

Pathway Diagram

The following diagram shows the key molecular relationships involving Proteostasis Triad Pulses: ISR + Autophagy + Chaperone Induction discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ideas-payload-proteostasis-triad-pulses

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-payload-proteostasis-triad-pulses
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a43681ae23f9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-payload-proteostasis-triad-pulses'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

42

Outgoing

83

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Proteostasis Triad Pulses: ISR + Autophagy + Chaperone Induction

Overview

Overview

Mechanistic Rationale

The Proteostasis Crisis in Neurodegeneration

Triple-Action Strategy

Why Pulsed Rather Than Continuous?

Evidence Base

Preclinical Evidence

ISR Modulation

Autophagy Induction

Chaperone Induction

Combination Approaches

Clinical Evidence

Biomarkers for Target Engagement

Implementation Roadmap

Preclinical Development (Years 1-3)

Clinical Development (Years 4-7)

Commercial Strategy

Actionable Next Steps

Immediate (0-3 months)

Near-term (3-12 months)

Medium-term (1-2 years)

Key Risks and Mitigations

Cross-Linking

See Also

External Links

Rubric Score

Rubric Score

Cross-Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Proteostasis Triad Pulses: ISR + Autophagy + Chaperone Induction

Overview

Overview

Mechanistic Rationale

The Proteostasis Crisis in Neurodegeneration

Triple-Action Strategy

Why Pulsed Rather Than Continuous?

Evidence Base

Preclinical Evidence

ISR Modulation

Autophagy Induction

Chaperone Induction

Combination Approaches

Clinical Evidence

Biomarkers for Target Engagement

Implementation Roadmap

Preclinical Development (Years 1-3)

Clinical Development (Years 4-7)

Commercial Strategy

Actionable Next Steps

Immediate (0-3 months)

Near-term (3-12 months)

Medium-term (1-2 years)

Key Risks and Mitigations

Cross-Linking

Related Mechanisms

Related Proteins

Related Therapies

Related Diseases

See Also

External Links

Rubric Score

Rubric Score

Cross-Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion